Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for ABBVIE

All Data per March 3, 2023

Industry:

Drug Manufacturers—General

Last Close:

156.06 USD

Expected Dividend:

3.61 %

Payoffs per Year:

4.0
Business Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Competitors View

Ordering

ABBVIE

USA
 1.03 4.28%
3.61%		 7.39% 5.46% 1.0 4.36
-9.47%		 43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN		 0.96 2.56%
0.0%		 22.5% 6.68% 1.0 4.24
-32.13%		 32.9 15.38% 77.21 2.0

PFIZER

USA		 0.95 3.64%
3.96%		 2.76% 3.76% 1.0 3.02
-11.11%		 49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR		 1.04 4.07%
2.74%		 1.15% 3.92% 1.0 11.56
-3.86%		 98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN		 1.05 4.24%
0.0%		 0.0% 3.88% 1.0 8.15
-17.26%		 35.15 18.52% 61.0 5.0

SANOFI

FRA		 1.01 3.78%
4.03%		 0.74% 3.58% 1.0 0.57
-12.18%		 51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA		 0.98 2.8%
3.1%		 1.83% 2.78% 1.0 0.5
-24.44%		 34.92 17.8% 32.88 7.0

MERCK & CO.

USA		 1.12 3.12%
2.64%		 2.24% 3.15% 1.0 2.31
-11.68%		 55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN		 0.96 1.88%
1.67%		 7.74% 2.44% 1.0 3.6
-15.61%		 35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA		 1.16 2.74%
3.6%		 5.91% 3.26% 1.0 0.15
-42.43%		 33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA		 1.04 2.43%
1.22%		 2.86% 2.52% 1.0 7.52
-12.71%		 42.91 5.87% 18.4 11.0

ROCHE

CHE		 0.92 3.28%
3.51%		 0.79% 3.11% 1.0 1.4
-15.85%		 37.23 2.14% 26.53 12.0

AMGEN

USA		 1.0 2.42%
3.28%		 8.46% 3.24% 1.0 3.5
-9.93%		 35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR		 0.96 5.37%
5.27%		 0.35% 5.0% -0.5 0.21
-24.56%		 49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN		 0.96 2.43%
0.0%		 1.74% 2.4% 1.0 1.09
-19.06%		 27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN		 0.93 2.21%
2.54%		 0.0% 2.02% 1.0 -0.41
-14.62%		 28.52 12.2% 71.29 16.0

BAYER

GER		 1.02 2.51%
3.99%		 4.7% 2.83% 0.5 -0.36
-58.76%		 36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA		 0.98 2.68%
0.0%		 0.0% 2.46% 1.0 -1.0
13.03%		 44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP		 0.98 1.5%
nan%		 4.84% 1.7% -0.5 0.24
-46.29%		 31.86 -1.95% 31.7 nan

Information for ABBVIE

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2013 52.81 1.60 3.03
2014 65.44 1.66 2.54
2015 59.24 2.02 3.41
2016 62.62 2.28 3.64
2017 96.71 2.56 2.65
2018 92.19 3.59 3.89
2019 88.54 5.35 6.04
2020 107.15 4.72 4.41
2021 135.40 5.20 3.84
2023 156.06 5.63 3.61

Fundamentals

Chart